JP2006512899A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512899A5
JP2006512899A5 JP2004526901A JP2004526901A JP2006512899A5 JP 2006512899 A5 JP2006512899 A5 JP 2006512899A5 JP 2004526901 A JP2004526901 A JP 2004526901A JP 2004526901 A JP2004526901 A JP 2004526901A JP 2006512899 A5 JP2006512899 A5 JP 2006512899A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004526901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512899A (ja
JP4528121B2 (ja
Filing date
Publication date
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Application filed filed Critical
Priority claimed from PCT/EP2003/008749 external-priority patent/WO2004014953A2/en
Publication of JP2006512899A publication Critical patent/JP2006512899A/ja
Publication of JP2006512899A5 publication Critical patent/JP2006512899A5/ja
Application granted granted Critical
Publication of JP4528121B2 publication Critical patent/JP4528121B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004526901A 2002-08-06 2003-08-05 抗ミエリン関連糖タンパク質（ｍａｇ）抗体 Expired - Fee Related JP4528121B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies
PCT/EP2003/008749 WO2004014953A2 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies

Publications (3)

Publication Number Publication Date
JP2006512899A JP2006512899A (ja) 2006-04-20
JP2006512899A5 true JP2006512899A5 (enExample) 2006-08-31
JP4528121B2 JP4528121B2 (ja) 2010-08-18

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004526901A Expired - Fee Related JP4528121B2 (ja) 2002-08-06 2003-08-05 抗ミエリン関連糖タンパク質（ｍａｇ）抗体

Country Status (23)

Country Link
US (2) US7612183B2 (enExample)
EP (1) EP1526868B1 (enExample)
JP (1) JP4528121B2 (enExample)
KR (1) KR101078459B1 (enExample)
CN (1) CN100542607C (enExample)
AR (1) AR040778A1 (enExample)
AU (1) AU2003255390B2 (enExample)
BR (1) BR0312456A (enExample)
CA (1) CA2494008C (enExample)
CY (1) CY1114919T1 (enExample)
DK (1) DK1526868T3 (enExample)
ES (1) ES2440652T3 (enExample)
IL (1) IL165478A (enExample)
IS (1) IS7576A (enExample)
MX (1) MXPA05001468A (enExample)
MY (1) MY148409A (enExample)
NO (1) NO333876B1 (enExample)
NZ (1) NZ537123A (enExample)
PL (1) PL211014B1 (enExample)
PT (1) PT1526868E (enExample)
SI (1) SI1526868T1 (enExample)
TW (1) TWI323265B (enExample)
WO (1) WO2004014953A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
WO2007139359A1 (en) * 2006-05-31 2007-12-06 Hanwha Chemical Corporation Vcam-1 specific monoclonal antibody
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
US20100291108A1 (en) * 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
PE20091964A1 (es) 2008-05-06 2010-01-09 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
CA2802376A1 (en) 2010-06-14 2011-12-22 Vaccinex, Inc. Anti-vegf antibodies and uses thereof
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
EP3083977B1 (en) 2013-12-20 2018-02-28 F. Hoffmann-La Roche AG Improved recombinant polypeptide production methods
PL3116887T3 (pl) 2014-03-13 2021-09-06 Universität Basel Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CN108026134A (zh) 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
BR112018006237A2 (pt) * 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
CN109481673A (zh) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 促进脑损伤神经修复的组合物及其应用与评价方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (da) 1987-02-19 1987-02-19 Axel Olsen Listesystem til foering af elektriske stroemforsynings- og/eller svagstroemsledere
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
FI93513C (fi) 1993-11-04 1995-04-25 Matti Kangasvuori Ketju sekä menetelmä ketjun tekemiseksi
DE69535133T2 (de) * 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5792743A (en) 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
CA2218599A1 (en) 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5932542A (en) 1995-06-27 1999-08-03 Research Foundation Of Cuny, Hunter College Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
NZ311174A (en) * 1995-06-30 1999-04-29 Mochida Pharm Co Ltd Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody
AU6858596A (en) 1995-08-25 1997-03-19 Johns Hopkins University School Of Medicine, The Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
DK1047449T3 (da) 1997-10-28 2004-01-26 Univ British Columbia Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response
WO1999053945A1 (en) 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
CA2343313A1 (en) * 1998-09-14 2000-03-23 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
SK287323B6 (sk) 1998-11-06 2010-07-07 University Of Z�Rich Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
CA2361124A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2001062907A1 (fr) 2000-02-22 2001-08-30 Medical & Biological Laboratories Co., Ltd. Bibliotheque d'anticorps
GB0103174D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Similar Documents

Publication Publication Date Title
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
JP2009511480A5 (enExample)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
RU2006123481A (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2020500538A5 (enExample)
JP2021531254A5 (enExample)
JP2012504955A5 (enExample)
JP2020517249A5 (enExample)
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
JP2018535650A5 (enExample)
JP2011506483A5 (enExample)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2003528052A5 (enExample)
JP2019522961A5 (enExample)
JP2010516229A5 (enExample)
RU2008129080A (ru) Средства и способы лечения опухолевых заболеваний
JP2010526028A5 (enExample)
JP2021501579A5 (enExample)
JP2010520290A5 (enExample)
JP2012532851A5 (enExample)
JP2015503909A5 (enExample)
JP2020500834A5 (enExample)
JP2020522281A5 (enExample)